Rangesh Abinand 4

What Happened

• Rangesh Abinand, CEO of TecoGen, reported two acquisitions on 2026-06-26: a restricted stock award of 174,081 shares and a derivative acquisition of 26,041 shares via an option exercise at $5.17 per share (total cost ≈ $134,632). The restricted award lists no per-share price (N/A) because it is an equity grant subject to vesting.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-30 (filed four days after the transaction; later than the typical 2-business-day deadline).
• Prices and values: 26,041 shares acquired at $5.17 each (≈ $134,632); 174,081 restricted shares reported as N/A for price (grant).
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: Grants and options are under the 2022 Stock Incentive Plan. The restricted stock award vests 25% per year (four-year vesting). The 26,041-share derivative is an incentive stock option under the same plan.
• No 10b5-1 plan, tax-withholding sale, or gift noted in the provided information.

Context

• The restricted stock award is subject to a multi-year vesting schedule (25% per year), so those shares are not fully transferable immediately. The derivative line indicates an option exercise — the CEO acquired shares by exercising incentive stock options at $5.17 each.
• These are acquisitions (insider buying/award), which investors often view as a more informative signal than routine sales; however, filings do not state intent or future plans. The late filing reduces timeliness of disclosure.